Cerebral Microvascular Accumulation of Tau Oligomers in Alzheimer’s Disease and Related Tauopathies

The importance of vascular contributions to cognitive impairment and dementia (VCID) associated with Alzheimer’s disease (AD) and related neurodegenerative diseases is increasingly recognized, however, the underlying mechanisms remain obscure. There is growing evidence that in addition to Aβ deposition, accumulation of hyperphosphorylated oligomeric tau contributes significantly to AD etiology. Tau oligomers are toxic and it has been suggested that they propagate in a “prion-like” fashion, inducing endogenous tau misfolding in cells. Their role in VCID, however, is not yet understood. The present study was designed to determine the severity of vascular deposition of oligomeric tau in the brain in patients with AD and related tauopathies, including dementia with Lewy bodies (DLB) and progressive supranuclear palsy (PSP). Further, we examined a potential link between vascular deposition of fibrillar Aβ and that of tau oligomers in the Tg2576 mouse model. We found that tau oligomers accumulate in cerebral microvasculature of human patients with AD and PSP, in association with vascular endothelial and smooth muscle cells. Cerebrovascular deposition of tau oligomers was also found in DLB patients. We also show that tau oligomers accumulate in cerebral microvasculature of Tg2576 mice, partially in association with cerebrovascular Aβ deposits. Thus, our findings add to the growing evidence for multifaceted microvascular involvement in the pathogenesis of AD and other neurodegenerative diseases. Accumulation of tau oligomers may represent a potential novel mechanism by which functional and structural integrity of the cerebral microvessels is compromised.

[1]  J. Whitwell,et al.  Alzheimer's disease neuroimaging , 2018, Current opinion in neurology.

[2]  Norbert Schuff,et al.  Early role of vascular dysregulation on late-onset Alzheimer's disease based on multifactorial data-driven analysis , 2016, Nature Communications.

[3]  S. A. Hussaini,et al.  Neuronal activity enhances tau propagation and tau pathology in vivo , 2016, Nature Neuroscience.

[4]  C. Moy,et al.  The Science of Vascular Contributions to Cognitive Impairment and Dementia (VCID): A Framework for Advancing Research Priorities in the Cerebrovascular Biology of Cognitive Decline , 2016, Cellular and Molecular Neurobiology.

[5]  A. Hofman,et al.  Cerebral Microbleeds and Cerebrovascular Reactivity in the General Population: The EDAN Study. , 2016, Journal of Alzheimer's disease : JAD.

[6]  U. Sengupta,et al.  Pathological Interface Between Oligomeric Alpha-Synuclein and Tau in Synucleinopathies , 2015, Biological Psychiatry.

[7]  M. Frosch,et al.  Matrix metalloproteinase 9–mediated intracerebral hemorrhage induced by cerebral amyloid angiopathy , 2015, Neurobiology of Aging.

[8]  J. Schneider,et al.  Vascular contributions to cognitive impairment and dementia including Alzheimer's disease , 2015, Alzheimer's & Dementia.

[9]  R. Barker,et al.  The role of tau in the pathological process and clinical expression of Huntington’s disease , 2015, Brain : a journal of neurology.

[10]  C. Dickey,et al.  Tau depletion prevents progressive blood-brain barrier damage in a mouse model of tauopathy , 2015, Acta neuropathologica communications.

[11]  U. Sengupta,et al.  Amyloid-β oligomers as a template for secondary amyloidosis in Alzheimer's disease , 2014, Neurobiology of Disease.

[12]  M. Ihara,et al.  New Therapeutic Approaches for Alzheimer’s Disease and Cerebral Amyloid Angiopathy , 2014, Front. Aging Neurosci..

[13]  R. Kayed,et al.  Advances in therapeutics for neurodegenerative tauopathies: moving toward the specific targeting of the most toxic tau species. , 2014, ACS chemical neuroscience.

[14]  U. Sengupta,et al.  Characterization of tau oligomeric seeds in progressive supranuclear palsy , 2014, Acta neuropathologica communications.

[15]  R. Huganir,et al.  Tau phosphorylation and tau mislocalization mediate soluble Aβ oligomer‐induced AMPA glutamate receptor signaling deficits , 2014, The European journal of neuroscience.

[16]  U. Sengupta,et al.  Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles , 2014, The Journal of Neuroscience.

[17]  M. Sierks,et al.  Trimeric Tau Is Toxic to Human Neuronal Cells at Low Nanomolar Concentrations , 2013, International journal of cell biology.

[18]  P. Fox,et al.  Chronic Rapamycin Restores Brain Vascular Integrity and Function Through NO Synthase Activation and Improves Memory in Symptomatic Mice Modeling Alzheimer’s Disease , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[19]  R. Kayed,et al.  Formation and Propagation of Tau Oligomeric Seeds , 2013, Front. Neurol..

[20]  D. Werring,et al.  Pathogenesis of cerebral microbleeds: In vivo imaging of amyloid and subcortical ischemic small vessel disease in 226 individuals with cognitive impairment , 2013, Annals of neurology.

[21]  T. Arendt,et al.  Tau Oligomers Impair Artificial Membrane Integrity and Cellular Viability* , 2012, The Journal of Biological Chemistry.

[22]  U. Sengupta,et al.  Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau , 2012, Scientific Reports.

[23]  U. Sengupta,et al.  Identification of oligomers at early stages of tau aggregation in Alzheimer's disease , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  J. Ghiso,et al.  Insights into Caspase-Mediated Apoptotic Pathways Induced by Amyloid-β in Cerebral Microvascular Endothelial Cells , 2011, Neurodegenerative Diseases.

[25]  B. Zlokovic.  Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders , 2011, Nature Reviews Neuroscience.

[26]  Jan Warnking,et al.  Impaired cerebral vasoreactivity to CO2 in Alzheimer's disease using BOLD fMRI , 2011, NeuroImage.

[27]  G. Jackson,et al.  Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies. , 2011, Current Alzheimer research.

[28]  U. Sengupta,et al.  Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice , 2011, Molecular Neurodegeneration.

[29]  K. Jellinger,et al.  Review: Sporadic cerebral amyloid angiopathy , 2011, Neuropathology and applied neurobiology.

[30]  R. Kayed,et al.  Preparation and characterization of neurotoxic tau oligomers. , 2010, Biochemistry.

[31]  P. Couraud,et al.  Differential activation of mitochondrial apoptotic pathways by vasculotropic amyloid‐β variants in cells composing the cerebral vessel walls , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  L. Mucke,et al.  Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.

[33]  Hyonchol Kim,et al.  Granular tau oligomers as intermediates of tau filaments. , 2007, Biochemistry.

[34]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[35]  Steven Song,et al.  The role of pericytes in blood-vessel formation and maintenance. , 2005, Neuro-oncology.

[36]  S. Love,et al.  Relationship of neurofibrillary pathology to cerebral amyloid angiopathy in Alzheimer's disease , 2005, Neuropathology and applied neurobiology.

[37]  A. Hofman,et al.  Cerebral hypoperfusion and clinical onset of dementia: The Rotterdam study , 2005, Annals of neurology.

[38]  C. Iadecola.  Neurovascular regulation in the normal brain and in Alzheimer's disease , 2004, Nature Reviews Neuroscience.

[39]  T. Lanz,et al.  Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype , 2003, Neurobiology of Disease.

[40]  M. Vitek,et al.  Tau is essential to β-amyloid-induced neurotoxicity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[41]  B. Hyman,et al.  APPSW Transgenic Mice Develop Age‐related Aβ Deposits and Neuropil Abnormalities, but no Neuronal Loss in CA1 , 1997, Journal of neuropathology and experimental neurology.

[42]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[43]  H. Wiśniewski,et al.  Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[44]  U. Sengupta,et al.  Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds. , 2014, Journal of Alzheimer's disease : JAD.

[45]  D. Bennett,et al.  AHA / ASA Scientific Statement Vascular Contributions to Cognitive Impairment and Dementia , 2011 .

[46]  Michela Gallagher,et al.  A specific amyloid-beta protein assembly in the brain impairs memory. , 2006, Nature.

[47]  M. Vitek,et al.  Tau is essential to beta -amyloid-induced neurotoxicity. , 2002, Proceedings of the National Academy of Sciences of the United States of America.